Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Vicenza
Clinical trial register · Italy

Clinical Trials in Vicenza, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC
6778
Studies in scope
all four open statuses
4069
Recruiting now
open to new participants
1018
Lead sponsors
across recruiting studies
Top sites
Milan 2843 Bologna 1305 Roma 1274 Naples 984 Rome 967
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sanofi3 Novartis Pharmaceuticals2 Merck Sharp & Dohme LLC2 FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS2 AstraZeneca2
Site location
Milan2843 Bologna1305 Roma1274 Naples984 Rome967
All 489 locations
Target enrolment
to

Trials with a site in Vicenza

34 of 6778 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Recruiting
Volume Removal Intolerance During Net Ultrafiltration in Acute Kidney Injury Patients
NCT07643597Acute Kidney Injury, Fluid Overload, Fluid Overload in Dialysis Patients, Critical Illness
Hospital Las Higueras
Observational
128
Vicenza
2026-07-06
Recruiting
Novartis Pharmaceuticals
Phase 2
60
Florence, Roma, Trieste, Vicenza
2026-06-26
Recruiting
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
NCT07504458Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
DrugsArsenic Trioxide·ATRA
Quetzal Therapeutics
Phase 3
150
Vicenza
2026-06-08
Active, closed
Intact Cord Placental Delivery vs Delayed Cord Clamping
NCT07713277Intact Cord Placental Delivery, Delayed Cord Clamping, Standard Delayed Cord Clamping, Timing of Cord Clamping
Azienda ULSS 8 Berica
Observational
1,979
Vicenza
2026-04-15
Recruiting
Hands-on vs Hands-off Techniques in Perineal Protection
NCT07492940Perineal Trauma, Hands-on Technique, Hands-of Technique, Manual Perineal Protection
Azienda ULSS 8 Berica
Observational
737
Vicenza
2026-03-05
Recruiting
A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
NCT07203768Polycythemia Vera, Thrombocythemia
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Observational
678
Pavia, Vicenza, Alessandria, Bergamo, Bologna, Brescia, Florence, Milan
2025-12-01
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
Ancona, Modena, Pisa, Vicenza
2025-11-28
Recruiting
Sanofi
Phase 3
60
Meldola, Milan, Naples, Torino, Vicenza
2025-10-24
Recruiting
Kedrion S.p.A.
Phase 3
40
Florence, Novara, Trieste, Torino, Vicenza
2025-08-13
Recruiting
AstraZeneca
Phase 2
100
Florence, Milan, Modena, Pisa, Rozzano, Udine, Vicenza
2025-07-17
Active, closed
FARAPULSE Workflow Assessment Registry
NCT06656884Atrial Fibrillation (AF)
Boston Scientific Corporation
Observational
524
Ferrara, Mestre, Monza, Rivoli, Vicenza
2025-05-06
Recruiting
Swedish Orphan Biovitrum
Phase 3
104
Catanzaro, Florence, Milan, Naples, Parma, Rome, Rozzano, Vicenza
2025-03-06
By invitation
Demographic and Interpopulation Variations in Evaluation and Results of TAVI
NCT07258706Aortic Stenosis, TAVI(Transcatheter Aortic Valve Implantation), Computed Tomography, Inflammatory Response During Cardiac Surgery
Poznan University of Medical Sciences
Observational
800
Vicenza
2025-01-01
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
130
Florence, Milan, Rozzano, Vicenza
2024-09-11
Recruiting
TRAns-Femoral Access Intravascular Lithotripsy Comparison With PTA in TAVI
NCT05873842Trans-femoral TAVI With Calcified Ilio-femoral Arteries
Rede Optimus Hospitalar SA
Observational
50
Ancona, Mestre, Treviso, Verona, Vicenza
2024-07-22
Recruiting
PENTA Foundation
Not applicable
3,080
Ferrara, Modena, Palermo, Vicenza
2024-05-28
Active, closed
Sanofi
Phase 3
1,541
Milan, Rozzano, Rome, Bologna, Catania, L’Aquila, Pisa, Vicenza
2024-05-08
Active, closed
AstraZeneca
Phase 3
594
Florence, Milan, Naples, Padova, Pisa, Vicenza
2024-03-04
Recruiting
The Viability Control of Human Endothelial Cells Before Keratoplasty (V-CHECK) Study
NCT05847387Corneal Transplant Failure, Corneal Endothelial Cell Loss
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Observational
135
Brescia, Bologna, Catanzaro, Roma, Venice, Vicenza
2023-12-01
Active, closed
Sanofi
Phase 2
999
Milan, Naples, Rome, Brescia, Vicenza
2023-04-03
Active, closed
Boston Scientific Corporation
Observational
1,173
Ancona, Mercogliano, Rivoli, Roma, Vicenza
2023-03-24
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Bologna, Florence, Roma, Trieste, Vicenza
2023-02-03
Recruiting
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Observational
429
Bergamo, Milan, Pavia, Varese, Padova, Verona, Vicenza, Alessandria
2022-09-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
280
Naples, Bologna, Meldola, Milan, Turin, Rome, Florence, Vicenza
2022-02-03
Recruiting
Blueprint Medicines Corporation
Phase 2/3
534
Milan, Florence, Bologna, Catania, Pavia, Salerno, Verona, Vicenza
2021-11-30
Active, closed
Loxo Oncology, Inc.
Phase 3
238
Viale Orazio Flacco, Monza (MB) -Settore E, Pisa, Rionero in Vulture, Vicenza, Alessandria, Bergamo, Brescia
2021-03-09
Active, closed
Bioverativ, a Sanofi company
Phase 3
261
Naples, Milan, Vicenza
2021-02-23
By invitation
Novo Nordisk A/S
Observational
60
Parma, Roma, Torino, Vicenza
2020-10-23
Active, closed
Galderma R&D
Phase 3
1,700
Bologna, L’Aquila, Roma, Rome, Rozzano, Vicenza
2019-12-30
Recruiting
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
NCT04065399Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia
DrugsCobicistat·Revumenib
Syndax Pharmaceuticals
Phase 1/2
447
Bologna, Meldola, Milan, Roma, Vicenza
2019-11-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
595
Roma, Orbassano, Vicenza, Arezzo, Catania, Milan, Naples, Pavia
2019-07-24
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Folinic acid·Fluorouracil·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
565
Meldola, Monza, Vicenza, Ancona, Bergamo, Cremona, Milan, Modena
2018-06-21
Active, closed
pharmaand GmbH
Phase 3
1,097
Aviano, Candiolo, Catania, Chieti, Naples, Roma, Vicenza
2018-05-14
Active, closed
Italfarmaco
Phase 2
90
Bari, Bergamo, Florence, Milan, Pescara, Pavia, Reggio Calabria, Vicenza
2013-03
Rows per page Showing 1–34 of 34
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-italy/city/vicenza

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 34 of those studies with a site in Vicenza.

How many clinical trials are recruiting in Vicenza?

17 of the 34 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 15 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Vicenza), 34 studies
PhaseStudiesRecruitingShare
Phase 314441.2%
Observational11632.4%
Phase 25314.7%
Phase 1/2225.9%
Not applicable112.9%
Phase 2/3112.9%

Most active sponsors

Lead sponsors with the most studies (Vicenza)
Lead sponsorStudiesRecruiting
Sanofi31
AstraZeneca21
Azienda ULSS 8 Berica21
Boston Scientific Corporation20
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS22
Merck Sharp & Dohme LLC20
Novartis Pharmaceuticals21
Astellas Pharma Global Development, Inc.10
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia11
Bioverativ, a Sanofi company10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.